In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans:: A critical role for tissue macrophages

被引:46
作者
Grinsell, M
Weinhold, LC
Cutler, JE
Han, YM
Kozel, TR [1 ]
机构
[1] Univ Nevada, Sch Med, Dept Microbiol 320, Reno, NV 89557 USA
[2] Univ Nevada, Cell & Mol Biol Program, Reno, NV 89557 USA
[3] Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA
关键词
D O I
10.1086/322787
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cryptococcus neoformans produces a life-threatening meningitis in patients who are immunocompromised by AIDS. A striking feature of cryptococcosis in AIDS is high serum levels of the major capsular polysaccharide, glucuronoxylomannan (GXM). Soluble GXM has numerous biologic activities that may contribute to the pathogenesis of infection. The objective of the study was to further understand in vivo processing of GXM. Mice were injected intravenously with GXM, and the tissue distribution was determined. A macrophage suicide technique that used liposome-encapsulated dichloromethylene diphosphonate determined the role of macrophages. GXM was cleared from serum with a half-life of 24-48 h but was retained for an indefinite period in tissues rich in cells of the mononuclear phagocyte system. Ablation of macrophages decreased GXM in the liver and spleen and increased serum GXM. The results identify a key role for macrophages in the clearance of GXM from serum and identify macrophages as a long-term reservoir for storage.
引用
收藏
页码:479 / 487
页数:9
相关论文
共 50 条
[1]  
BLOOMFIELD N, 1963, P SOC EXP BIOL MED, V114, P64, DOI 10.3181/00379727-114-28586
[2]   CRYPTOCOCCUS NEOFORMANS .I. NONENCAPSULATED MUTANTS [J].
BULMER, GS ;
SANS, MD ;
GUNN, CM .
JOURNAL OF BACTERIOLOGY, 1967, 94 (05) :1475-&
[3]   CRYPTOCOCCUS NEOFORMANS .3. INHIBITION OF PHAGOCYTOSIS [J].
BULMER, GS ;
SANS, MD .
JOURNAL OF BACTERIOLOGY, 1968, 95 (01) :5-&
[4]   CRYPTOCOCCAL ANTIGEN-DETECTION FROM THE URINE OF AIDS PATIENTS [J].
CHAPINROBERTSON, K ;
BECHTEL, C ;
WAYCOTT, S ;
KONTNICK, C ;
EDBERG, SC .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1993, 17 (03) :197-201
[5]   POLYSACCHARIDE ANTIGENS OF THE CAPSULE OF CRYPTOCOCCUS-NEOFORMANS [J].
CHERNIAK, R ;
SUNDSTROM, JB .
INFECTION AND IMMUNITY, 1994, 62 (05) :1507-1512
[6]   STRUCTURE AND ANTIGENIC ACTIVITY OF THE CAPSULAR POLYSACCHARIDE OF CRYPTOCOCCUS-NEOFORMANS SEROTYPE-A [J].
CHERNIAK, R ;
REISS, E ;
SLODKI, ME ;
PLATTNER, RD ;
BLUMER, SO .
MOLECULAR IMMUNOLOGY, 1980, 17 (08) :1025-1032
[7]   INFECTIONS WITH CRYPTOCOCCUS-NEOFORMANS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].
CHUCK, SL ;
SANDE, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (12) :794-799
[8]   Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components [J].
Delfino, D ;
Cianci, L ;
Lupis, E ;
Celeste, A ;
Petrelli, ML ;
Curro, F ;
Cusumano, V ;
Teti, G .
INFECTION AND IMMUNITY, 1997, 65 (06) :2454-2456
[9]   ELEVATED CEREBROSPINAL-FLUID PRESSURES IN PATIENTS WITH CRYPTOCOCCAL MENINGITIS AND ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
DENNING, DW ;
ARMSTRONG, RW ;
LEWIS, BH ;
STEVENS, DA .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 (03) :267-272
[10]   PROGNOSTIC FACTORS IN CRYPTOCOCCAL MENINGITIS - STUDY IN 111 CASES [J].
DIAMOND, RD ;
BENNETT, JE .
ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) :176-181